posted
http://finance.yahoo.com/news/Generex-Announces-USFDA-pz-37374504.html?x=0&.v=1 Generex Announces USFDA Approval of Use of Company's Flagship Buccal Insulin Product, Generex Oral-lyn(TM), Under the USFDA'S Treatment Investigational New Drug (IND) Program Press Release Source: Generex Biotechnology Corp. On Thursday September 10, 2009, 9:00 am EDT Buzz up! 0 Print Companies:Generex Biotechnology Corp.
WORCESTER, Mass., Sept. 10, 2009 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (Nasdaq:GNBT - News) (www.generex.com), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, today announced that the U.S. Food and Drug Administration (FDA) has granted approval for the treatment use of Generex Oral-lyn(tm) under the FDA's Treatment Investigational New Drug (IND) program.
The FDA's Treatment IND program allows companies to provide early access to investigational drugs for patients with serious or life-threatening conditions for which there is no satisfactory alternative treatment. Drugs that are granted approval by the FDA for the Treatment IND program must demonstrate the prospect of efficacy through clinical testing.
Under a structured Treatment IND protocol, Generex Oral-lyn(tm) will be provided to patients with serious or life-threatening Type 1 or Type 2 diabetes mellitus, with no satisfactory alternative therapy available for the treatment of diabetes, and who are not eligible to participate in the Company's ongoing global Phase III pivotal clinical trial.
This Treatment IND will be open to eligible patients that comply with the inclusion/exclusion criteria of the protocol, including those who are taking currently approved anti-diabetic medications. There are no oral or injectable medications contraindicated for this IND program.
In order to learn more about the availability of Generex Oral-lyn(tm) under the IND Treatment program, as per FDA requirements, the Company will be providing information within the www.ClinicalTrials.gov website. Details will include study design and participating sites and/or physicians. Please note that the drug will be available only through physicians who are registered in the Treatment IND program.
"We are excited about having the opportunity to meet the needs of American patients living with diabetes who have no satisfactory alternative treatment and have contacted the Company, based on their special needs, about possible access to Generex Oral-lyn(tm)," stated Anna Gluskin, Generex's President and Chief Executive Officer. "This opportunity to provide those in critical need of Generex Oral-lyn(tm) will continue while the pivotal Phase III study concludes and the Company prepares for its New Drug Submission with the USFDA and other major health authorities in key markets."
About Generex Biotechnology Corporation
Generex is engaged in the research, development and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist(tm) device. The Company's flagship product, oral insulin (Generex Oral-lyn(tm)), which is available for sale in India, Lebanon, Algeria, and Ecuador for the treatment of subjects with Type-1 and Type-2 diabetes, is in Phase III clinical trials at several sites around the world. Antigen Express, Inc. is a wholly owned subsidiary of Generex. The core platform technologies of Antigen Express comprise immunotherapeutics for the treatment of malignant, infectious, allergic, and autoimmune diseases. For more information, visit the Generex website at www.generex.com or the Antigen Express website at www.antigenexpress.com.
This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plans," "intends," "believes," "will," "estimates," "forecasts," "projects," or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials. Because of this, statements regarding the expected timing of clinical trials cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any "phase" of clinical trials. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.
Contact: American Capital Ventures, Inc.Investor Relations Contact:Howard Gostfrand1-877-918-0774Beckerman Public RelationsMedia Contact:Jerry Schranz201-465-8020
-------------------- All post are my opinion. Do your own DD. Who's clicking your buy/sell button!? Posts: 7800 | From: Virginia | Registered: May 2006
| IP: Logged |
posted
FDA allows emergency use of Generex diabetes drug Generex says ruling will allow it to provide Generex Oral-lyn to some patients before approval On Thursday September 10, 2009, 6:25 pm EDT Buzz up! 9 Print.Companies:Generex Biotechnology Corp. WORCESTER, Mass. (AP) -- Generex Biotechnology Corp. said Thursday the Food and Drug Administration approved experimental use of its diabetes drug candidate Generex Oral-lyn.
The FDA approved what is called a treatment investigational new drug program, which allows drug makers to make unapproved drug available to patients with dangerous illnesses who don't have a satisfactory treatment.
Generex Oral-lyn will be provided to patients with life-threatening type 1 or type 2 diabetes who are not eligible for a current late-stage trial.
The company makes drugs that are taken through the inner lining of the mouth, for use against metabolic diseases.
During the regular trading day, Generex stock surged 15 cents, or 22.6 percent, to close at 83 cents. The shares slipped to 81 cents in trading after hours.
-------------------- All post are my opinion. Do your own DD. Who's clicking your buy/sell button!? Posts: 7800 | From: Virginia | Registered: May 2006
| IP: Logged |
posted
NASDAQ Last Sale 0.8111 0.02 2.41% Volume 58,763,566 Previous Close $ 0.83 Today's High $ 1.06 Today's Low $ 0.69 52 Wk High $ 1.14 52 Wk Low $ .08
After Hours Trade Reporting Pre-Market Charts | After Hours Charts After Hours Last: $ .819 After Hours High: $ .94 After Hours Volume: 514,100 After Hours Low: $ .78
-------------------- All post are my opinion. Do your own DD. Who's clicking your buy/sell button!? Posts: 7800 | From: Virginia | Registered: May 2006
| IP: Logged |
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
